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Purpose: To evaluate the RPGRIP1-deficient miniature longhaired dachshund (MLHD) dog as a potential candidate for
gene therapy.
Methods: Six RPGRIP1-deficient MLHD dogs from our dog colony have been observed for two years using a variety of
noninvasive procedures. These included bilateral full-field electroretinograms (ERG) to evaluate retinal function, fundus
photographs to evaluate retinal vascularization, and optical coherence tomographs (OCT) to evaluate retinal thickness.
We also performed histological examination of hematoxylin- and eosin-stained retinal sections as well as sections labeled
in situ by the terminal dUTP nick end labeling (TUNEL) method.
Results: ERG findings showed that as early as 2 months of age, cone function was lost while rod function was preserved.
However, by 9 months of age, both cone and rod functions could not be detected. Functional visual assessment based on
the ability to avoid obstacles showed that vision was retained up to the age of 11 months. Both OCT and histopathology
studies revealed a progressive thinning of the outer nuclear layer (ONL) over the first 2 years of age. TUNEL labeling
identified apoptotic photoreceptor cell death as the cause of this thinning of the ONL.
Conclusions: A treatment strategy should consist in initiating gene therapy as early as possible after birth to prevent or
delay the loss of rod function. In the MLHD, successful subretinal delivery of a therapeutic vector is feasible at 2 months
of age and may prevent or delay the loss of rod function.
Inherited retinal degenerations are a heterogeneous group
of  disorders  that  nearly  always  share  one  critical  feature:
degeneration  of  photoreceptors.  Retinal  dystrophies  often
lead to blindness. Currently, there are no effective treatments.
To study the pathophysiology of retinal degeneration, animal
models for which the genetic basis is understood are used.
They share clinical features with their human couterparts and
serve  as  valuable  tools  to  aid  in  the  development  of
therapeuties.  For  example,  the  close  similarities  between
humans and dogs, in terms of the clinical characteristics of
disease  resulting  from  retinal  pigment  epithelium-specific
protein 65 kDa (RPE65) gene mutations, make the RPE65−/−
Briard  dog  a  valuable  model  for  the  evaluation  of  gene
therapy. Several groups, including ours, have now reported
restoration of vision in RPE65−/− dogs using recombinant
adeno  associated  virus  (rAAV)  mediated  delivery  of  the
human RPE65 gene [1-3]. The success of the RPE65−/− dog
gene therapy experiments was crucial in the development of
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human  clinical  trials  to  treat  patients  affected  with  Leber
congenital  amaurosis  (LCA)  or  early  onset  retinal
degeneration linked to a mutation in RPE65 [4-6].
The  mutation  involved  in  a  retinal  degeneration
previously described in miniature longhaired dachshunds has
been  identified  [7,8].  This  mutation  consists  of  a  44  bp
insertion  in  exon  2  of  the  retinitis  pigmentosa  GTPase
regulator-interacting  protein  1  (RPGRIP1)  gene,  and
introduces a premature stop codon [9].
Genetic  defects  in  the  retinitis  pigmentosa  GTPase
regulator (RPGR) gene cause retinitis pigmentosa and defects
in  RPGRIP1  cause  LCA  [10,11].  A  study  reporting  a
comprehensive mutational analysis of all known genes in 179
unrelated patients showed that RPGRIP1 accounts for 4.5%
of the cases [12].
Patients with RPGRIP1 mutations have degeneration of
both rod and cone photoreceptor cells, and in early life they
experience a severe loss of central acuity, which leads to
nystagmus. The functions of RPGR and RPGRIP1 are not
fully understood. Both RPGR and RPGRIP1 localize in the
photoreceptor connecting cilium, a thin bridge linking the cell
body  and  the  light-sensing  outer  segment.  A  study  of
RPGRIP1−/− mice demonstrated that RPGRIP1 is a stable
polymer in the connecting cilium where it tethers RPGR and
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349that RPGR depends on RPGRIP1 for subcellular localization
and normal function [13]. This same study also suggested that
RPGRIP1 is required for disk morphogenesis, putatively by
regulating actin cytoskeleton dynamics.
The objective of this study was to evaluate this LCA
canine model as a potential candidate for gene therapy. For
this  purpose,  we  further  characterized  the  kinetics  of  the
retinal  degeneration  and  the  disease  phenotype  in  the
RPGRIP1  deficient  miniature  longhaired  dachshund
(MLHD).
METHODS
RPGRIP1-deficient dogs: A colony of MLHD dogs carrying
the  RPGRIP1  mutation  (a  44  nucleotide  insertion  that
introduces a premature stop codon) was developed at the
Boisbonne center (Ecole Nationale Vétérinaire de Nantes,
Nantes, France). All animals were cared for in accordance
with  the  Association  for  Research  in  Vision  and
Ophthalmology (ARVO) statement for the use of animals in
ophthalmic  and  vision  research.  Dogs  were  housed  in
purpose-built, environmentally enriched facility with 12 h
light-12 h dark cycle, they were fed with commercial diets and
provided  with  water  ad  lib.  Affected  dogs  A1-A4  were
monitored from birth to 2 years of age. A1 died at the age of
11 months from an intestinal obstruction. Dogs A5 (a 10-year-
old affected dog) and A6 (a 2-month-old affected dog) were
sacrificed for histology study (Table 1).
Electroretinography: Dogs were dark-adapted for 20 min, and
electroretinograms  (ERGs)  were  performed  under  general
anesthesia. Dogs were anesthetized with a combination of
40 µg/kg medetomidine (Domitor®; Pfizer, Paris, France) with
5 mg/kg ketamine (Imalgène®; Rhone Merieux, Toulouse,
France), mixed in one syringe and given intravenously in a
single dose. After endotracheal intubation, anesthesia was
maintained with 1.5% isofluorane. Dogs were monitored by
clinical  observations,  respiratory  rate  measurements,
temperature measurements, oxymetry, and capnography. Rod
and cone function was tested using simultaneous bilateral
flash photopic and scotopic electroretinography. ERGs were
recorded  in  a  standardized  fashion,  according  to  the
International Society for Clinical Electrophysiology of Vision
(ISCEV) [14], using a computer-based system (Neuropack
μ™ MEB-9102K, Nikon-Kohden, Tokyo, Japan) and contact
lens electrodes (ERGjet®; Microponent, Le Cret-du-Locie,
Switzerland).
In fully dark-adapted dogs, attenuated white flash (0.028
cd.s.m−2) was used to elicit a rod ERG b-wave. Four flashes,
presented at a rate of 0.5 Hz, were used to average the rod
system response.
To elicit a maximal mixed rod and cone response, we used
a single white light flash (2.8 cd.s. m−2) . The maximal mixed
rod and cone responses were averaged by using three flashes,
presented  at  a  rate  of  0.1  Hz.  Following  a  10  min  light
adaptation, cone function was tested with 1 Hz white light
flashes, and the cone flicker was tested with 30 Hz white light
flashes, both in addition to a continuous rod desensitizing
white background light. Ten to 20 responses were averaged
for light-adapted recordings.
The b-wave amplitude was measured from the a-wave
peak to the b-wave peak. Flicker amplitude was measured
from the trough to the peak. Measurement method followed
the  recommendations  in  the  ISCEV  Standard  for  Clinical
electroretinography.
Behavioral  studies:  Using  a  camcorder,  we  recorded  the
visual behavior of affected dogs walking through an obstacle
course in normal light. The number of collisions incurred by
each dog as it went through the course was compared at
different time points after birth (every month over a 2 year
period).
Fundus photography: The pupils of the dogs were dilated 20
min  before  anesthesia  using  tropicamide  (Ciba  Vision
Faure®;  Novartis,  Annonay,  France)  and  phenylephrine
hydrochloride (10% Neosynephrine®; Novartis). Dogs were
anesthetized with a combination of 40 µg/kg medetomidine
(Domitor®,  Pfizer,  Paris,  France)  with  5  mg/kg  ketamine





(once a month) H&E IF TUNEL
A1 2, 4, 9 m 2, 9 m nd 2–10 m 11 m nd 11 m
A2 2, 4, 9, 12 m 2, 12 m 5, 12 m 2–24 m 28 m nd 28 m
A3 2, 4, 9, 12 m 2, 12 m nd 2–24 m nd nd nd
A4 2, 4, 9, 12 m 2, 12 m nd 2–24 m nd nd nd
A5 nd nd 10 y nd 10 y nd nd
A6 nd nd nd nd 2 m 2 m 2 m
NA1 6 m nd nd nd nd nd nd
NA2 nd nd nd nd 2 m 2 m 2 m
Abbreviations: affected dog (A); nonaffected dog (NA); electroretinography (ERG); OCT is optical coherence tomography;
hematoxylin- and eosin-stained sections (H&E); immunofluorescence stained sections (IF); sections labeled in situ by the
terminal dUTP nick end labeling method (TUNEL); months (m); years (y); not done (nd).
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OCT(Imalgène®), mixed in one syringe and given intravenously in
a single dose. Maintenance with isofluorane was not needed.
After endotracheal intubation, dogs were clinically observed
and their respiratory rates were monitored. Fundi were imaged
using a Canon UVI retinal camera connected to a digital
imaging system (Lhedioph win software; Lheritier SA, Saint-
Ouen l’Aumône, France).
Optical  coherence  tomography:  Retinal  morphology  was
assessed  by  optical  coherence  tomography  (OCT;  Stratus
3000; Zeiss, Jena, Germany). Dilatation of the pupils and
intravenous  anesthesia  of  the  animals  were  performed  as
described in the previous section. At different time points, a
3 mm horizontal line scan was performed in the area located
above the optical nerve head.
Histology: Eyecups were obtained from normal and affected
dogs and were fixed for 48 h in Bouin’s solution (Laurylab,
Saint Fons, France). Tissue sections (5–7 µm thick) were cut
from  paraffin-embedded  blocks  on  a  microtome.  For
histopathological examinations, sections were stained using a
standard  hematoxylin  and  eosin  staining  protocol.  H&S
sections were viewed with bright-light microscopy (Nikon,
Champigny sur Marne, France).
For immunofluorescence evaluation, paraffin-embedded
sections were deparaffinized and rehydrated with phosphate
buffered  saline  (PBS,  0.9  mM  CaCl2,  0.49  mM  MgSO4,
2.68 mM KCl, 1.47 mM KH2PO4, 136.89 mM NaCl, 8.10 mM
NaH2PO4). The sections were blocked with 5% BSA in 0.2%
Tween /PBS for 30 min at room temperature, washed at room
temperature in 0.2% Tween/PBS with 1% BSA. Sections were
then  incubated  overnight  at  4  °C  with  1:100  mouse
monoclonal anti-Rho4D2 antibody [15] (kindly provided by
Dr.  Molday,  University  of  British  Columbia,  Vancouver,
Canada) or 1:1,000 peanut lectin agglutinin-conjugated with
fluorescein isothiocyanate (PNA-FITC; Vector Laboratories
Inc., Burlingame, CA) diluted in 0.2% Tween /PBS. Sections
were washed with 1% BSA in 0.2% Tween/PBS at room
temperature and labeled with anti-Rho4D2 antibody. They
were  then  incubated  with  1:400  FITC-conjugated  donkey
anti-mouse secondary antibody (Jackson ImmunoResearch
Laboratories  Inc.,  Newmarket,  England)  diluted  in  0.2%
Figure  1.  Bilateral  full-field
electroretinographic  recordings  of
RPGRIP1-deficient  dogs.  A:
Heterozygous carrier NA1 at the age of
6 months. B: Affected dog A1 at the age
of 2, 4, and 9 months. C: Affected dog
A2 at the age of 2, 4, 9, and 12 months.
D: Affected dog A3 at the age of 2, 4, 9,
and 12 months. E: Affected dog A4 at
the age of 2, 4, 9, and 12 months. The
top  two  recordings  are  low  and  high
intensity  scotopic  responses.  The
bottom two recordings show photopic
responses to light-adapted single flash
and 30 Hz flicker stimuli.
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351Figure 2. Fundus photographs in RPGRIP1-deficient dogs. A, B: A1 at the age of 2 and 9 months. C, D: A2 at the age of 2 and 12 months. E, F:
A3 at the age of 2 and 12 months. G, H: A4 at the age of 2 and 12 months. There is progressive thinning of the retinal vasculature and an
increase in hyperreflectivity of the tapetal area of the fundus.
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352Tween/PBS for 1 h 30 min at room temperature. Sections were
then washed with 1% BSA in 0.2% PBS/Tween.
TUNEL assay: To detect apoptosis, we employed the TUNEL
technique, using a commercially available kit (In situ Cell
Death  Detection  Kit,  Fluorescein;  Roche,  Mannheim,
Germany). TUNEL staining was performed according to the
manufacturer's instructions and as described by Labat-Moleur
[16].  A  positive  control  was  used.  This  was  obtained  by
inducing DNA fragmentation with DNaseI treatment before
TUNEL  staining,  which  mimics  the  DNA  fragmentation
associated with apoptosis. The negative control consisted of
performing the TUNEL labeling without including the TdT
enzyme.
Statistical analysis: Retinal thickness values were obtained
with OCT on both eyes from dogs A1, A2, A3, and A4. At
each time point (2, 6, 9, 12, 15, 18, 21, and 28 months) the
thickness of the retinas was expressed as mean (µm)±1 SD.
Comparisons of retinal thickness were performed by Student's
t-test. A p<0.05 was accepted as significant. The Student test
required two assumptions are met: 1) the samples must be
distributed as a Gaussian distribution, which was a reasonable
assumption; 2) the variances of the two samples must be equal.
The second assumption was checked using a Fisher Test.
For  time  points  2,  6,  and  9  months,  the  number  of
measurements was n=8, and included measurements taken
from dogs A1, A2, A3, and A4. For time points 12, 15, 18, 21,
and 28 months, the number of measurements was n=6, and
included dogs A2, A3, and A4 (A1 died at the age 11 months).
RESULTS
Kinetics of retinal function loss in RPGRIP1-deficient dogs:
Retinal function was tested using simultaneous bilateral full-
field flash ERG (Figure 1). For all affected MLHD, the cone
function (cone ERG and 30 Hz flicker) were barely detectable
as early as 2 months of age. At this same time point, the rod
function  was  similar  between  heterozygous  carrier  and
affected animals, but progressively declined thereafter. At 4
months of age, the rod function was dramatically reduced for
A2, A3, and A4 while A1 still displayed respectable signals.
The  ERG  responses  became  undetectable  at  the  age  of  9
months  for  A1,  A2,  A3,  and  by  14  months  for  A4.  It  is
interesting to note the substantial variation within the kinetic
of retinal function loss from animal to animal. However, for
all affected dogs, no retinal function could be detected by 14
months.
Kinetics  of  vision  loss  in  RPGRIP1-deficient  dogs:  We
evaluated vision in all 4 affected MLHD using behavioral
testing at different time points. This evaluation started at 2
months of age and was repeated every month over a 2 year
period. Visual assessment was based on the ability to avoid
obstacles in normal light. The obstacle course was arranged
such that the placement of obstacles was unique from trial to
trial. All dogs consistently avoided obstacles at the age of 9
months.  At  11  months,  A1,  A2  and  A3  failed  to  avoid
obstacles, indicating they had loss of vision (a movie of A2 in
the obstacle course can be viewed in Appendix 1). For A4,
loss of vision was observed at 15 months. For all affected
dogs, that residual vision was still detected during the 1–2
months  following  a  complete  loss  of  a  measurable  ERG
signal.
Thinning  of  retinal  blood  vessel  and  decrease  of  retinal
thickness: Retinal morphology was monitored by color fundus
photographs and by OCT in A2 to A4 for up to 2 years and up
to 10 months for A1. For each affected MLHD, color fundus
photographs displayed a progressive and dramatic thinning of
the  retinal  vascularization,  accompanied  by  a
hyperreflectivity of the tapetal area of the fundus, over a 12
month period (Figure 2).
OCT is a non-contact, optical imaging technique that
measures  the  intensity  of  backscattered  light  [17,18].  It
produces  a  cross-sectional  image,  analogous  to  B-scan
ultrasonography, but based on the optical reflectivity of the
tissue,  and  thus,  by  using  light  instead  of  sound  waves,
provides an image with greater resolution. OCT imaging was
performed in all affected animals at different time points.
Long-term  OCT  monitoring  in  A1-A4  documented  an
important decrease of the retinal thickness between 5 and 12
months  (Figure  3A,B).  This  decrease  was  statistically
significant  over  the  first  2  years  of  life  (Figure  4).
Interestingly,  OCT  imaging  of  A5,  an  older  RPGRIP1-
deficient  dog  that  was  monitored  at  the  age  of  10  years,
displayed  the  RPE  layer  but  no  neuroretina,  suggesting  a
complete  degeneration  of  neuroretinal  cells  (Figure  3C).
Moreover, dogs A2-A4 displayed lens opacities at the age of
21 months. Lens photographs of A5 at the age of 10 years
showed a total cataract (data not shown).
Histopathology and apoptosis of photoreceptors: To better
evaluate the retinal alterations observed on the OCT images,
we sacrificed A6 at the age of 2 months, A1 at the age of 11
months, A2 at the age of 28 months, and A5 at the age of 10
years. The eyes were used for histopathological examination
(Figure 5). Examination of hematoxylin- and eosin-stained
sections revealed thinning of the outer nuclear layer between
the age of 2 and 28 months, reflecting the progressive loss of
photoreceptor cells. As seen in dog A5, by the age of 10 years,
and as observed by OCT, a thin gliotic retina remained visible
on histologic section with a complete lack of the photoreceptor
layer.
Immunofluorescence staining of the retina of A6 was
performed, using the PNA-FITC lectin and the Rho4D2-FITC
antibody. Distinct cone and rod labeling (Figure 6F,H) were
observed, suggesting that rods and cones were still present at
2 months of age.
To test whether apoptotic cell death was the cause of
retinal  thinning  of  over  time,  we  employed  the  TUNEL
technique to stain sections from A6, A1, and A2 for apoptotic
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TUNEL compared to normal retina. Most of the apoptotic
nuclei were detected in the outer nuclear layer, with some
nuclei detected in the inner nuclear layer and no signal in the
ganglion cell layer (Figure 7).
DISCUSSION
In  this  study,  RPGRIP1-deficient  MLHD  dogs  were
monitored clinically to define the optimal therapeutic window
for retinal gene therapy. Analysis of the ERG findings showed
that as early as 2 months of age, cone function was lost, while
rod  function  was  preserved.  While  cone  function  was
undetectable  at  this  time  point,  the  cone  photoreceptors
Figure 3. Images of OCT recordings of
RPGRIP1-deficient  dogs.  The  insets
show  the  localization  of  the  3mm
horizontal line scan above the optical
nerve  head.  Notable  decrease  of  the
retinal  thickness  is  observed  in  the
affected dog A2 between 5 (A) and 12
months  (B).  Surprisingly,  extreme
thinning  is  seen  in  the  10-year-old
affected dog A5 (C).
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9  months  of  age,  both  cone  and  rod  functions  were
undetectable. Interestingly, at this time point, assessment of
each dog’s ability to avoid obstacles showed that functional
vision is retained up to the age of 11 months. Both OCT and
histopathology studies revealed a progressive thinning of the
neuroretina  over  the  first  2  years  of  age.  TUNEL  assay
indicated that the apoptotic photoreceptor cell death was the
mechanism of this thinning of the neuroretina.
In contrast to the study by Curtis and Barnett [7], which
described what was thought to be a rod-cone dystrophy in the
MLHD, and in accordance with the recent findings of Turney
et al. [8], our results indicated that the RPGRIP1-deficient
MLHD manifested a cone-rod dystrophy. Our ERG findings
matched the Turney et al. [8] study. In their study, the ERG
of a 6-week-old affected MLHD showed significant reduction
of the 30 Hz flicker response.
Cone-rod dystrophies are rare. This is the first canine
model of cone-rod dystrophy with a mutation that has been
characterized [9]. A veterinary ophthalmological report from
Kijas et al. [19] described a cone-rod dystrophy in pit bull
terrier dogs; however, the causal gene was not identified. In
this last model, the cone dysfunction was synchronous with
the rod dysfunction, in contrast to what we have documented
in the RPGRIP1-deficient model, where the rod responses
appear  to  be  relatively  better  preserved  early  in  disease.
Another cone-rod dystrophy was described in a standard wire
haired dachshund, also displaying early functional changes of
cones [20].
Although the ERG recordings were undetectable at the
age of 9 months in several RPGRIP1-deficient dogs, these
same affected dogs still retained some residual functional
vision at this same age point. Functional vision persisted in at
least one dog up to 14 months of age, at a time when the ERG
was undetectable in this animal. This analysis suggests that
evaluation both of functional vision using a behavioral test, as
well as retinal function, using ERG, will have to be performed
to evaluate the efficacy of any future treatment using this
model. This is in sharp contrast to what we have observed in
gene therapy treated RPE65−/− dogs, where rescue of retinal
function  was  directly  associated  to  an  improvement  of
functional vision as assessed by behavioral studies [3].
The progressive thinning of the ONL observed by OCT
and on the retinal sections was due to apoptotic photoreceptor
cell death. The photoreceptor cell death appears to progress
in a similar rate over the first 2 years since the proportion of
TUNEL-labeled photoreceptors remains consistent among the
3 different time points (2, 11, and 28 months; Figure 8). These
results in the MLHD are different from those observed in the
X-linked progressive retinal atrophy 2 (XLPRA2), which is
characterized genetically by a frameshift mutation in exon 15
of the RPGR gene. In this model, a biphasic pattern of cell
death was found, with an initial phase, from 4 to 12 weeks of
age, and then a more gradual decrease after 12 weeks [21].
It  was  surprising  to  observe  that  for  the  10-year-old
RPGRIP1-deficient  dog,  not  only  had  the  outer  retina
disappeared  but  so  had  the  inner  retina.  An  analysis  of
hematoxylin- and eosin-counterstained sections from dogs
between 2 months and 10 years of age did not reveal any
inflammatory cells. To our knowledge, this phenomenon of
complete neuroretinal degeneration has not been described in
any other animal models of LCA or retinitis pigmentosa.
To date, the clinical literature on RPGRIP1-LCA patients
clearly documents early and severe visual disturbances with
nystagmus, abnormal visual acuity, nondetectable ERGs, and
fundus features of retinal degeneration [22,23]. The close
similarities  between  the  clinical  disease  characteristics
resulting from RPGRIP1 gene mutations in humans and in the
dog make this RPGRIP1-deficient MHLD a valuable model
for the evaluation of gene therapy.
Recent  success  of  AAV-mediated  RPGRIP1  gene
transfer in a murine model of RPGRIP1-LCA is encouraging
[24]. However, the evaluation of pre-clinical gene therapy in
the eye of canine genetic models is far more desirable with
respect  to  future  clinical  development;  the  canine  eye  is
anatomically more similar to the human eye than the mouse
counterpart. The dog ocular anatomic features are of similar
proportion. Also, the surgical procedures for vector delivery
Figure  4.  Decrease  of  full  retinal
thickness over time as observed on OCT
scans.  Bars  (+1  standard  deviation)
represent retinal thickness measured on
retinal sections from dogs of different
ages. The Student t-test was performed
to compare the mean retinal thickness at
different stages of the disease. A p<0.05
was considered significant. The retinal
thickness  decrease  was  significant
between  2  months  and  28  months
(p=8.7E07).
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355Figure 5. Histological sections of RPGRIP1-deficient dog’s retinas. A: Normal dog NA2 at the age of 2 months. B: Affected dog A6 at the
age of 2 months. C: Affected dog A1 at the age of 11 months. D: Affected dog A2 at the age of 28 months. E: Affected dog A5 at the age of
10 years. These results confirm the thinning of the retina observed on OCT images. Abbreviations: retinal pigment epithelium (RPE); outer
segments (OS); inner segments (IS); outer nuclear layer (ONL); outer plexiform layer (OPL); inner nuclear layer (INL); inner plexiform layer
(IPL); ganglion cell layer (GCL). The scale bar represents 100 µm.
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356Figure 6. Light micrographs and immunofluorescent staining. A,B,C,D: Retina of the non affected dog NA2. E,F,G,H: Retina of the 2 months
old affected dog A6. B,F: Rod labeling with anti-Rho4D2 antibody. D,H: Cone labeling with PNA-FITC lectin. These results show that both
the rods and cones are still present at the age of 2 months in affected dogs. Abbreviations: retinal pigment epithelium (RPE); outer segments
(OS); inner segments (IS); outer nuclear layer (ONL); outer plexiform layer (OPL); inner nuclear layer (INL); inner plexiform layer (IPL);
ganglion cell layer (GCL). The scale bar represents 50 µm.
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357and the amount of vector injected in the dog will be similar to
what will be used in humans. In addition, dogs, which are
relatively outbred compared to murine models, have greater
immunological and biologic similarity to humans, which is
vital and essential for determining the tolerance of vectors
before clinical trials.
Recombinant AAV-mediated gene therapy has already
been shown successful in the first canine model of LCA, the
RPE65−/− dog. This RPGRIP1-deficient model is an attractive
alternative LCA canine model in the sense that, in contrast to
RPE65,  it  is  not  a  rod-cone  dystrophy  but  a  cone-rod
dystrophy and that the cells to target are not the RPE but the
photoreceptors. A photoreceptor defect is more difficult to
treat than a RPE defect, and a large animal model of such a
defect has great intrinsic value.
In  conclusion,  we  have  characterized  the  kinetics  of
functional and structural changes that occur in RPGRIP1-
deficient dogs. The results of this present study suggest a
therapeutic strategy that consists of initiating gene therapy as
early as possible after birth. Considering the small size of the
MLHD dogs (120–200 g at birth) and our preliminary surgical
data  (unpublished  results),  accurate  transvitreal  subretinal
injection  is  not  possible  in  dogs  younger  than  2  months.
Successful subretinal delivery of a therapeutic vector will be
feasible by 2 months of age and may prevent or delay the loss
of rod function. This is a valuable spontaneous animal model
Figure 7. TUNEL assay on normal and affected dogs. A: Retina of the normal dog NA2 displayed no TUNEL-positive labeling. B: Retina of
the affected dog A6 at the age of 2 months treated with DnaseI (positive control). C: Retina of the affected dog A6 at the age of 2 months
treated with label solution only (negative control). TUNEL staining (D,E,F) and corresponding light micrographs (G,H,I) of the retinas of
affected dogs. (D,G) retina of the affected dog A6 at the age of 2 months, (E,H) retina of the affected dog A1 at the age of 11 months and
(F,I) retina of the affected dog A2 at the age of 28 months. TUNEL staining revealed apoptotic cells in all affected dogs, mostly in the outer
nuclear layer, indicating apoptosis of photoreceptor cells. Abbreviations: retinal pigment epithelium (RPE); outer segments (OS); inner
segments (IS); outer nuclear layer (ONL); outer plexiform layer (OPL); inner nuclear layer (INL); inner plexiform layer (IPL); ganglion cell
layer (GCL). The scale bar represents 100 µm.
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358that represents a unique and important tool to assess the in
vivo efficacy of photoreceptor targeted gene based therapeutic
strategies for cone-rod dystrophies.
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360Appendix 1. Behavioral tests.
Visual function was evaluated using behavioral testing
based on the ability of each animal to avoid obstacles in
normal light. The treated affected A2 avoided obstacles at the
age of 8 months but consistently failed to avoid obstacles after
the age of 11 months, seen in the movie in Appendix 1. To
access the movie, click or select the words “Appendix 1.” This
will initiate the download of a compressed (.mov) archive that
contains the movie.
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